Celgene Corp (NASDAQ:CELG)

CAPS Rating: 5 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Results 1 - 20 of 244 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar Steffsea (42.04) Submitted: 12/12/2014 1:07:10 PM : Outperform Start Price: $114.87 CELG Score: -0.02

Always on top

Recs

0
Member Avatar FrankoJames (93.70) Submitted: 12/12/2014 7:50:35 AM : Outperform Start Price: $116.37 CELG Score: -0.36

This is a high flying biotech that I need to further research without government spy cams from my country or any other country and/or state watching over me as I type on my Sony laptop. I believe that the need for cancer and immune-inflammatory cures will continue in the future as the population of the human race increases over the course of time.

Recs

0
Member Avatar coleman205 (20.99) Submitted: 12/1/2014 11:29:35 PM : Outperform Start Price: $114.00 CELG Score: +2.44

solid

Recs

0
Member Avatar sullyz0r (73.79) Submitted: 11/25/2014 10:43:45 PM : Outperform Start Price: $111.46 CELG Score: +5.50

As much as CELG is in itself a great stock, I often find that, for many of the small biotech companies I want to invest in, CELG has already taken a large stake. So I get not only a great company, but sort of a biotech fund by some great investment minds.

Recs

0
Member Avatar Orffy (54.86) Submitted: 11/20/2014 4:17:10 AM : Outperform Start Price: $105.76 CELG Score: +9.69

Management has been effective in building a strong pipeline of drugs. Revlimid, which is growing at 19% according to the recent quarterly report, has been versatile in terms of its uses thereby extending the value of the drug to future years. In addition, the company has high hopes for some of its drugs like Abraxane and Otezla (which Management hints could be a blockbuster seller). Celgene also seems to lack some of the pricing PR problems that have plagued Gilead, which seems to lessen the chance of Government Regulators assessing Celgene's pricing strategies. Celgene has been able to demonstrate a strong growth in earnings over the last few years, above 20% on a q-o-q basis. This kind of growth will propel Celgene to higher valuations in the future. With Management estimating EPS targets of $4.50 in 2015 and $7.00 by 2017, we could see price targets as high as $210 on a 30X 2017 EPS estimation, which is in-line with Biogen Idec's current valuation. If Celgene were to rise to $210 by this time in 2017, it would represent nearly a 25% compounded growth rate in the share price. That's not bad!

Recs

0
Member Avatar jimda98 (< 20) Submitted: 11/10/2014 5:26:46 PM : Outperform Start Price: $108.00 CELG Score: +7.29

The pipeline of drugs continue to improve and be successfully accepted by the regulators in various regions.

Recs

0
Member Avatar moonlightsail (< 20) Submitted: 10/23/2014 2:42:16 PM : Outperform Start Price: $100.63 CELG Score: +11.04

Drug stock with treatments for cancer and Crone's Disease with new upward earnings.

Recs

0
Member Avatar Tophinater (37.86) Submitted: 10/20/2014 3:35:58 PM : Outperform Start Price: $91.73 CELG Score: +19.14

Cancer and heart disease now kill more than 50% of Americans.

Recs

0
Member Avatar boomertom (30.74) Submitted: 9/30/2014 2:48:32 PM : Outperform Start Price: $94.67 CELG Score: +19.04

Almost unlimited potential.

Recs

1
Member Avatar afketter (89.57) Submitted: 5/7/2014 10:05:17 PM : Outperform Start Price: $72.49 CELG Score: +51.62

Celgene has been brought down due to the whole biotech sector dropping, but they have solid earnings and are cheap on a 2016 basis. Not all of biotech will recover, but CELG will be one that moves a lot higher in the next 2 years

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 5/7/2014 6:06:11 PM : Underperform Start Price: $87.26 CELG Score: -30.42

Biotech bull market top

Recs

0
Member Avatar TerryFool (55.34) Submitted: 4/21/2014 8:05:51 AM : Outperform Start Price: $69.58 CELG Score: +58.59

INVEST BUY@ 140 TP 193 CAPS 4

Recs

1
Member Avatar awallejr (77.67) Submitted: 4/10/2014 5:18:40 PM : Outperform Start Price: $68.46 CELG Score: +57.80

Might be a little early but oversold.

Recs

0
Member Avatar ShoreDoc (46.78) Submitted: 4/9/2014 4:12:55 PM : Outperform Start Price: $73.86 CELG Score: +48.28

pipeline, valuation

Recs

0
Member Avatar DrGoldin (99.71) Submitted: 3/29/2014 2:25:12 AM : Outperform Start Price: $57.33 CELG Score: +74.63

The annihilation of Celgene continues, and a few years down the road people are going to wonder what on earth investors were thinking in March of 2014. Sitting tight with this one.

Recs

0
Member Avatar jbond009 (61.99) Submitted: 3/25/2014 8:24:38 PM : Outperform Start Price: $72.86 CELG Score: +50.41

Extremely oversold, very low P/E ratio

Recs

0
Member Avatar Chemdawg (26.74) Submitted: 3/7/2014 2:09:37 AM : Outperform Start Price: $79.06 CELG Score: +38.87

lots of old people in this country ...plus obama care

Recs

0
Member Avatar herodotous (< 20) Submitted: 2/4/2014 1:59:44 AM : Outperform Start Price: $74.54 CELG Score: +39.16

Excellent pipeline and prospects for continued growth.

Recs

0
Member Avatar klarcbarr (45.22) Submitted: 1/15/2014 5:25:47 AM : Outperform Start Price: $83.90 CELG Score: +27.49

The company inspires overall confidence through process and innovation. The blazing track record and robust pipeline forces me to conclude this one is a no-brainer.

Recs

0
Member Avatar gypsystem (57.26) Submitted: 1/11/2014 12:47:38 AM : Outperform Start Price: $85.24 CELG Score: +25.06

Great pipeline

Featured Broker Partners


Advertisement